Reviewing Myriad Genetics (NASDAQ:MYGN) and Lucira Health (NASDAQ:LHDXQ)
Reviewing Myriad Genetics (NASDAQ:MYGN) and Lucira Health (NASDAQ:LHDXQ)
Myriad Genetics (NASDAQ:MYGN – Get Rating) and Lucira Health (NASDAQ:LHDXQ – Get Rating) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, profitability, risk and analyst recommendations.
Myriad Genetics（納斯達克股票代碼：MYGN — 獲取評級）和 Lucira Health（納斯達克股票代碼：LHDXQ — 獲取評級）都是小盤股醫療公司，但哪項是優越的投資？我們將根據兩家公司的股息、收益、估值、機構所有權、盈利能力、風險和分析師建議對比這兩家公司。
Profitability
盈利能力
This table compares Myriad Genetics and Lucira Health's net margins, return on equity and return on assets.
該表比較了Myriad Genetics和Lucira Health的淨利潤率、股本回報率和資產回報率。
| Net Margins | Return on Equity | Return on Assets | |
| Myriad Genetics | -16.51% | -5.83% | -4.42% |
| Lucira Health | -67.54% | -13.55% | -8.47% |
| 淨利潤 | 股本回報率 | 資產回報率 | |
| 無數的遺傳學 | -16.51% | -5.83% | -4.42% |
| 露西拉健康 | -67.54% | -13.55% | -8.47% |
Analyst Recommendations
分析師建議
This is a summary of recent recommendations and price targets for Myriad Genetics and Lucira Health, as reported by MarketBeat.com.
據Marketbeat.com報道，這是Myriad Genetics和Lucira Health最近提出的建議和目標價格的摘要。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Myriad Genetics | 0 | 2 | 1 | 0 | 2.33 |
| Lucira Health | 0 | 0 | 0 | 0 | N/A |
| 賣出評級 | 持有評級 | 買入評級 | 強勁的買入評級 | 評分分數 | |
| 無數的遺傳學 | 0 | 2 | 1 | 0 | 2.33 |
| 露西拉健康 | 0 | 0 | 0 | 0 | 不適用 |
Myriad Genetics currently has a consensus price target of $27.00, indicating a potential upside of 24.42%. Given Myriad Genetics' higher possible upside, equities research analysts plainly believe Myriad Genetics is more favorable than Lucira Health.
Myriad Genetics目前的共識目標股價爲27.00美元，表明潛在的上漲空間爲24.42％。鑑於Myriad Genetics可能有更高的上行空間，股票研究分析師顯然認爲Myriad Genetics比Lucira Health更有利。
Earnings & Valuation
收益與估值
This table compares Myriad Genetics and Lucira Health's revenue, earnings per share and valuation.
該表比較了Myriad Genetics和Lucira Health的收入、每股收益和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Myriad Genetics | $678.40 million | 2.61 | -$112.00 million | ($1.39) | -15.61 |
| Lucira Health | $93.06 million | 0.01 | -$64.83 million | ($3.58) | -0.01 |
| 總收入 | 價格/銷售比率 | 淨收入 | 每股收益 | 市盈率 | |
| 無數的遺傳學 | 6.7840 億美元 | 2.61 | -1.120 億美元 | (1.39 美元) | -15.61 |
| 露西拉健康 | 9306 萬美元 | 0.01 | -6,483 萬美元 | (3.58 美元) | -0.01 |
Lucira Health has lower revenue, but higher earnings than Myriad Genetics. Myriad Genetics is trading at a lower price-to-earnings ratio than Lucira Health, indicating that it is currently the more affordable of the two stocks.
Lucira Health的收入較低，但收益高於Myriad Genetics。Myriad Genetics的交易市盈率低於Lucira Health，這表明它目前是這兩隻股票中更實惠的一隻。
Institutional & Insider Ownership
機構和內部所有權
99.1% of Myriad Genetics shares are owned by institutional investors. Comparatively, 57.0% of Lucira Health shares are owned by institutional investors. 1.8% of Myriad Genetics shares are owned by insiders. Comparatively, 30.4% of Lucira Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Myriad Genetics的99.1％的股份由機構投資者持有。相比之下，Lucira Health的股票中有57.0％由機構投資者持有。Myriad Genetics的1.8％的股票由內部人士持有。相比之下，Lucira Health的股份中有30.4％由內部人士持有。強大的機構所有權表明捐贈基金、對沖基金和大型基金經理認爲股票有望實現長期增長。
Risk and Volatility
風險和波動性
Myriad Genetics has a beta of 1.84, meaning that its share price is 84% more volatile than the S&P 500. Comparatively, Lucira Health has a beta of 3.36, meaning that its share price is 236% more volatile than the S&P 500.
Myriad Genetics的beta值爲1.84，這意味着其股價的波動性比標準普爾500指數高84％。相比之下，Lucira Health的beta值爲3.36，這意味着其股價的波動性比標準普爾500指數高236％。
Summary
摘要
Myriad Genetics beats Lucira Health on 9 of the 13 factors compared between the two stocks.
在兩隻股票比較的13個因素中，Myriad Genetics在9個因素上擊敗了Lucira Health。
About Myriad Genetics
關於《無數遺傳學》
(Get Rating)
（獲取評級）
Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual's risk of developing a disease later in life. The Other segment offers testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.
Myriad Genetics, Inc. 從事變革性分子診斷測試的發現、開發和營銷。它通過診斷和其他部門運營。診斷部門提供測試和合作開發測試服務，旨在評估個人在以後的生活中患上疾病的風險。其他部門爲製藥、生物技術和醫學研究行業、研發和患者臨床服務提供測試產品和服務，還包括企業服務。該公司由 Walter A. Gilbert、Mark H. Skolnick 和 Peter D. Meldrum 於 1991 年 5 月創立，總部位於猶他州鹽湖城。
About Lucira Health
關於 Lucira Health
(Get Rating)
（獲取評級）
Lucira Health Inc. is a medical technology company. It is focused on the development and commercialization of transformative and infectious disease test kits. Lucira Health Inc. is based in Emeryville, California.
Lucira Health Inc. 是一家醫療技術公司。它專注於變革性和傳染病檢測試劑盒的開發和商業化。Lucira Health Inc. 總部位於加利福尼亞州的埃默裏維爾。
Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.
接收《Myriad Genetics Daily》的 -在下面輸入您的電子郵件地址，即可通過Marketbeat.com的免費每日電子郵件時事通訊接收Myriad Genetics及相關公司的最新新聞和分析師評級的簡明每日摘要。
譯文內容由第三人軟體翻譯。